The study on phenotyping and predicting prognosis of patients with pulmonary arterial hypertension with cardiopulmonary comorbidities

The study on phenotyping and predicting prognosis of patients with pulmonary arterial hypertension with cardiopulmonary comorbidities - CAPLAM study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056065

Enrollment

500

Registered

2025-04-15

Start date

2025-04-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Idiopathic and hereditary PAH at age 16 years or older from the date of approval for implementation through December 31, 2028

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
All-cause mortality in registered patients	—

Secondary

Measure	Time frame
Lung transplantation, atrial septal perforation, worsening NYHA functional class, conditions requiring clinical intensification with poor reduction in mean PA and PVR with therapeutic intervention, hospitalization for pulmonary hypertension, elevated liver enzymes, edema, other serious drug side effects, pregnancy	—

Countries

Japan

Contacts

Public ContactShiro Adachi

Nagoya University Hospital Cardiology

sadachi@med.nagoya-u.ac.jp0527412111

Outcome results